Research ArticleSpecial Section on Epigenetic Regulation of Drug Metabolizing Enzymes and Transporters
Potential Role of Epigenetic Mechanisms in the Regulation of Drug Metabolism and Transport
Magnus Ingelman-Sundberg, Xiao-Bo Zhong, Oliver Hankinson, Sudheer Beedanagari, Ai-Ming Yu, Lai Peng and Yoichi Osawa
Drug Metabolism and Disposition October 2013, 41 (10) 1725-1731; DOI: https://doi.org/10.1124/dmd.113.053157
Magnus Ingelman-Sundberg
Department of Physiology and Pharmacology, Section of Pharmacogenetics, Karolinska Institutet, Stockholm, Sweden (M.I.-S.); Department of Pharmaceutical Sciences, University of Connecticut, Storrs, Connecticut (X.-B.Z., L.P.); Interdepartmental Molecular Toxicology Program and the Department of Pathology and Laboratory Medicine, University of California, Los Angeles, California (O.H., S.B.); Department of Biochemistry and Molecular Medicine, University of California at Davis School of Medicine, Sacramento, California (A.-M.Y.); and Department of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan (Y.O.)
Xiao-Bo Zhong
Department of Physiology and Pharmacology, Section of Pharmacogenetics, Karolinska Institutet, Stockholm, Sweden (M.I.-S.); Department of Pharmaceutical Sciences, University of Connecticut, Storrs, Connecticut (X.-B.Z., L.P.); Interdepartmental Molecular Toxicology Program and the Department of Pathology and Laboratory Medicine, University of California, Los Angeles, California (O.H., S.B.); Department of Biochemistry and Molecular Medicine, University of California at Davis School of Medicine, Sacramento, California (A.-M.Y.); and Department of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan (Y.O.)
Oliver Hankinson
Department of Physiology and Pharmacology, Section of Pharmacogenetics, Karolinska Institutet, Stockholm, Sweden (M.I.-S.); Department of Pharmaceutical Sciences, University of Connecticut, Storrs, Connecticut (X.-B.Z., L.P.); Interdepartmental Molecular Toxicology Program and the Department of Pathology and Laboratory Medicine, University of California, Los Angeles, California (O.H., S.B.); Department of Biochemistry and Molecular Medicine, University of California at Davis School of Medicine, Sacramento, California (A.-M.Y.); and Department of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan (Y.O.)
Sudheer Beedanagari
Department of Physiology and Pharmacology, Section of Pharmacogenetics, Karolinska Institutet, Stockholm, Sweden (M.I.-S.); Department of Pharmaceutical Sciences, University of Connecticut, Storrs, Connecticut (X.-B.Z., L.P.); Interdepartmental Molecular Toxicology Program and the Department of Pathology and Laboratory Medicine, University of California, Los Angeles, California (O.H., S.B.); Department of Biochemistry and Molecular Medicine, University of California at Davis School of Medicine, Sacramento, California (A.-M.Y.); and Department of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan (Y.O.)
Ai-Ming Yu
Department of Physiology and Pharmacology, Section of Pharmacogenetics, Karolinska Institutet, Stockholm, Sweden (M.I.-S.); Department of Pharmaceutical Sciences, University of Connecticut, Storrs, Connecticut (X.-B.Z., L.P.); Interdepartmental Molecular Toxicology Program and the Department of Pathology and Laboratory Medicine, University of California, Los Angeles, California (O.H., S.B.); Department of Biochemistry and Molecular Medicine, University of California at Davis School of Medicine, Sacramento, California (A.-M.Y.); and Department of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan (Y.O.)
Lai Peng
Department of Physiology and Pharmacology, Section of Pharmacogenetics, Karolinska Institutet, Stockholm, Sweden (M.I.-S.); Department of Pharmaceutical Sciences, University of Connecticut, Storrs, Connecticut (X.-B.Z., L.P.); Interdepartmental Molecular Toxicology Program and the Department of Pathology and Laboratory Medicine, University of California, Los Angeles, California (O.H., S.B.); Department of Biochemistry and Molecular Medicine, University of California at Davis School of Medicine, Sacramento, California (A.-M.Y.); and Department of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan (Y.O.)
Yoichi Osawa
Department of Physiology and Pharmacology, Section of Pharmacogenetics, Karolinska Institutet, Stockholm, Sweden (M.I.-S.); Department of Pharmaceutical Sciences, University of Connecticut, Storrs, Connecticut (X.-B.Z., L.P.); Interdepartmental Molecular Toxicology Program and the Department of Pathology and Laboratory Medicine, University of California, Los Angeles, California (O.H., S.B.); Department of Biochemistry and Molecular Medicine, University of California at Davis School of Medicine, Sacramento, California (A.-M.Y.); and Department of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan (Y.O.)
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
In this issue
Research ArticleSpecial Section on Epigenetic Regulation of Drug Metabolizing Enzymes and Transporters
Epigenetic Mechanisms in Drug Disposition
Magnus Ingelman-Sundberg, Xiao-Bo Zhong, Oliver Hankinson, Sudheer Beedanagari, Ai-Ming Yu, Lai Peng and Yoichi Osawa
Drug Metabolism and Disposition October 1, 2013, 41 (10) 1725-1731; DOI: https://doi.org/10.1124/dmd.113.053157
Research ArticleSpecial Section on Epigenetic Regulation of Drug Metabolizing Enzymes and Transporters
Epigenetic Mechanisms in Drug Disposition
Magnus Ingelman-Sundberg, Xiao-Bo Zhong, Oliver Hankinson, Sudheer Beedanagari, Ai-Ming Yu, Lai Peng and Yoichi Osawa
Drug Metabolism and Disposition October 1, 2013, 41 (10) 1725-1731; DOI: https://doi.org/10.1124/dmd.113.053157
Jump to section
- Article
- Abstract
- Introduction
- Overview of Genetic and Epigenetic Mechanisms Underlying Variable Drug Metabolism and Drug Response (M.I.-S.)
- Role of Epigenetic Mechanisms in Differential Regulation of the Dioxin-Inducible Human CYP1A1 and CYP1B1 Genes (O.H. and S.B.)
- Chromatin Interactions, Epigenomics, and Transcriptional Outcomes in Response to Xenobiotics (X.-B.Z.)
- Noncoding MicroRNAs in the Control of Drug Metabolism and Transport (A.-M.Y)
- Long Noncoding RNAs and Transcriptional and Post-Transcriptional Regulation of Cytochromes P450 in Mouse Liver during Maturation (L.P.)
- Summary
- Authorship Contributions
- Footnotes
- Abbreviations
- References
- Figures & Data
- Info & Metrics
- eLetters
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement